Query author contributions in Reactome
Reactome depends on collaboration between our curation team and outside experts to
assemble and peer-review its pathway modules. The integration of ORCID within Reactome
enables us to meet a key challenge with authoring, curating and reviewing biological
information by incentivizing and crediting the external experts that contribute their
expertise and time to the Reactome curation process. More information is available at
ORCID and Reactome.
If you have an ORCID ID that is not listed on this page, please
forward this information to us and we will update your Reactome pathway records.
Details on Person Rothfels, Karen, 2020-09-26
| Class:Id | InstanceEdit:9701293 |
|---|
| _displayName | Rothfels, Karen, 2020-09-26 |
|---|
| _timestamp | 2020-09-26 21:52:35 |
|---|
| author | [Person:1226097] Rothfels, Karen |
|---|
| dateTime | 2020-09-26 21:51:45 |
|---|
| (created) | [LiteratureReference:9701290] Nucleophosmin-anaplastic lymphoma kinase: the ultimate oncogene and therapeutic target
[Person:9701291] Wasik, Mariusz
[LiteratureReference:9701292] Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3
[LiteratureReference:9701294] Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)
[Person:9701295] Wysocka, Maria
[Person:9701296] Frantz, C
[Person:9701297] Chatterjee, Devasis
[Person:9701298] Riera, Ludovica
[LiteratureReference:9701299] IL-2R common gamma-chain is epigenetically silenced by nucleophosphin-anaplastic lymphoma kinase (NPM-ALK) and acts as a tumor suppressor by targeting NPM-ALK
[Person:9701300] Timar, Botond |
|---|
|
[Change default viewing format]
|
No pathways have been reviewed or authored by Rothfels, Karen, 2020-09-26 (9701293)
